Hikma Pharmaceuticals PLC
HKMPFOTCHealthcare● Active
$19.07
+$1.07(+5.94%)
Market Cap$4.1B
P/E Ratio—
52W High$27.96
52W Low$16.3425
Hikma Pharmaceuticals PLC (HKMPF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · HKMPF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $3.42B | $3.13B | $2.88B | $2.52B | $2.55B |
| Cost of Revenue | $2.05B | $1.71B | $1.47B | $1.25B | $1.25B |
| Gross Profit | $1.37B | $1.42B | $1.41B | $1.26B | $1.30B |
| Gross Margin %(computed) | 40.04% | 45.25% | 48.94% | 50.26% | 50.96% |
| Operating Expenses | |||||
| R&D Expenses | $0.15B | $0.14B | $0.15B | $0.14B | $0.14B |
| G&A Expenses | $0.00B | $0.57B | $0.64B | $0.51B | $0.49B |
| Total Operating Expenses | $0.73B | $0.80B | $1.04B | $0.98B | $0.72B |
| Operating Income | $0.64B | $0.61B | $0.37B | $0.28B | $0.58B |
| Operating Margin %(computed) | 18.63% | 19.57% | 12.77% | 11.20% | 22.80% |
| Interest Income | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.11B | $0.07B | $0.09B | $0.07B | $0.06B |
| Income Before Tax | $0.53B | $0.46B | $0.28B | $0.23B | $0.54B |
| Income Tax Expense | $0.11B | $0.09B | $0.09B | $0.04B | $0.12B |
| Net Income | $0.41B | $0.36B | $0.19B | $0.19B | $0.42B |
| Net Margin %(computed) | 12.00% | 11.48% | 6.61% | 7.47% | 16.49% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $1.86 | $1.62 | $0.85 | $0.84 | $1.82 |
| Wtd Avg Shares | 0.22B | 0.22B | 0.22B | 0.22B | 0.23B |
| EBITDA | $0.85B | $0.79B | $0.79B | $0.69B | $0.70B |
| EBITDA Margin %(computed) | 24.96% | 25.17% | 27.51% | 27.45% | 27.61% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Hikma Pharmaceuticals PLC data
About Hikma Pharmaceuticals PLC (HKMPF) Income Statement
Hikma Pharmaceuticals PLC (HKMPF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, HKMPF reported revenue of $3.42B, gross profit of $1.37B (gross margin 40.04%), and net income of $0.41B — a net profit margin of 12.00%.
Frequently asked questions
HKMPF · 4 questionsHikma Pharmaceuticals PLC (HKMPF) reported revenue of $3.42B for 2025, up 9.5% year-over-year.
HKMPF revenueHKMPF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09